Re: Separation Agreement and General ReleaseSeparation Agreement and General Release • November 5th, 2015 • Ophthotech Corp. • Pharmaceutical preparations
This letter agreement (the “Letter Agreement”) confirms our agreement concerning your separation from Ophthotech Corporation (“Ophthotech” or the “Company”). Subject to the terms of this Letter Agreement, your employment will end effective July 31, 2015 (the “Separation Date”). By signing a copy of this Letter Agreement in the space provided below, you agree to the terms and conditions set forth herein.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDMENT NO. 1 TO THE CLINICAL MANUFACTURING AND SUPPLY AGREEMENT BY AND BETWEEN AGILENT TECHNOLOGIES, INC. AND...Clinical Manufacturing and Supply Agreement • November 5th, 2015 • Ophthotech Corp. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) amends the Clinical Manufacturing and Supply Agreement (the “Agreement”) by and between Agilent Technologies, Inc. (“Agilent”) and Ophthotech Corporation (“Customer”) dated May 2, 2014 (“Effective Date”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTCommercial Manufacturing and Supply Agreement • November 5th, 2015 • Ophthotech Corp. • Pharmaceutical preparations • New York
This Commercial Manufacturing and Supply Agreement (this “Agreement”) is entered into by and between AGILENT TECHNOLOGIES, INC., a Delaware corporation, having a principal office at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (“Agilent”) and OPHTHOTECH CORPORATION, a Delaware corporation, having a principal office at One Penn Plaza, Suite 1924, New York, NY 10119 (“Customer”) effective as of September 3, 2015 (the “Effective Date”). Agilent and Customer are each referred to herein as a “Party” and together as the “Parties”.
